Search your stocks

Share

Profile

COHANCECohance Lifesciences Ltd.

916.2(+0.38%)

1W: -10.50%

1M: -5.09%

1Y: +36.28%

Financials

Charts

YoY Net Sales

Operating Margin

EPS Growth

Pros & Cons

POSITIVES

Revenue growth of 15% in the latest quarter compared to the previous quarter indicates strong market demand.
Improved gross margin at 35%, reflecting better cost management and pricing strategies.
Operational efficiency has increased, with a reduction in operating expenses by 10%.

NEGATIVES

Net income declined by 5% in the latest quarter, highlighting potential challenges in profitability.
Debt levels have risen, increasing financial risk and interest obligations.
Inventory turnover has decreased, suggesting potential issues in sales or overproduction.

Quarterly Results Data

Field	Trend	Sep 23	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25
Revenue		231.05	219.82	252.93	230.69	257.72	307.15	402.02	549.31
Expenses		145.49	168.70	199.13	165.76	172.34	213.13	360.99	492.62
Operating Profit		85.57	51.12	53.80	64.93	85.38	94.02	41.03	56.69
Other Income		19.84	14.34	17.05	18.16	14.12	15.71	10.57	14.17
Interest		0.50	1.27	2.30	1.60	1.67	3.33	5.75	10.18
Depreciation		11.89	12.75	17.25	13.40	16.96	20.35	26.78	45.14
Profit Before Tax		105.41	65.47	70.85	83.09	99.50	109.73	51.60	62.76
Tax		25.84	18.71	17.48	22.32	17.52	26.44	12.87	16.36
Net Profit		79.56	46.75	53.37	60.77	81.98	83.29	38.73	46.40
Eps in Rs		3.13	1.84	2.10	2.39	3.23	3.26	1.65	1.28